{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:09:52Z","timestamp":1791274192828,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Advantageous Specialty of Traditional Chinese Medicine"},{"name":"Chongqing Key Discipline of Traditional Chinese Medicine"},{"name":"Chongqing Key Specialty of Clinical Pharmacy"},{"name":"Cultivation Discipline of Chongqing Traditional Chinese Medicine Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04927-9","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:44:43Z","timestamp":1774716283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Zhonghua","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"25","key":"4927_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"3","key":"4927_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.semdp.2020.03.001","volume":"37","author":"JR Hassler","year":"2020","unstructured":"Hassler JR. IgA nephropathy: a brief review. Semin Diagn Pathol. 2020;37(3):143\u20137.","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"4927_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, et al. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"4927_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0002-9343(90)90300-3","volume":"89","author":"FP Schena","year":"1990","unstructured":"Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 1990;89(2):209\u201315.","journal-title":"Am J Med"},{"issue":"6","key":"4927_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4927_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/jheor.2021.26129","volume":"8","author":"CS Kwon","year":"2021","unstructured":"Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res. 2021;8(2):36\u201345.","journal-title":"J Health Econ Outcomes Res"},{"key":"4927_CR7","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","volume":"11","author":"J Barratt","year":"2024","unstructured":"Barratt J, Lafayette RA, Floege J. Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne). 2024;11:1461879.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4927_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stefansson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324.","journal-title":"Kidney Int"},{"key":"4927_CR9","doi-asserted-by":"publisher","first-page":"572754","DOI":"10.3389\/fimmu.2020.572754","volume":"11","author":"H Selvaskandan","year":"2020","unstructured":"Selvaskandan H, Shi S, Twaij S, et al. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol. 2020;11:572754.","journal-title":"Front Immunol"},{"issue":"4S","key":"4927_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"BH Rovin","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(4S):S1\u201371.","journal-title":"Kidney Int"},{"issue":"3","key":"4927_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ekir.2024.12.007","volume":"10","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Zhao Y, Chen M, et al. A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment. Kidney Int Rep. 2024;10(3):935\u20139.","journal-title":"Kidney Int Rep"},{"issue":"10405","key":"4927_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"key":"4927_CR13","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.2147\/DDDT.S383138","volume":"18","author":"J Barratt","year":"2024","unstructured":"Barratt J, Kristensen J, Pedersen C, et al. Insights on Nefecon(\u00ae), a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des Devel Ther. 2024;18:3415\u201328.","journal-title":"Drug Des Devel Ther"},{"key":"4927_CR14","doi-asserted-by":"crossref","unstructured":"Hwang S, Ramjee L, Patel M et al. EE336 Budget impact analysis of Nefecon for the treatment of primary IgA nephropathy in the United States. Value Health. 2022. 25(7, Supplement):S400.","DOI":"10.1016\/j.jval.2022.04.581"},{"issue":"9","key":"4927_CR15","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Liu X, et al. Exploring novel adverse events of Nefecon. Kidney Int Rep. 2024;9(9):2705\u201317.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"4927_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4927_CR17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4927_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000519973","volume":"2","author":"K Scionti","year":"2021","unstructured":"Scionti K, Molyneux K, Selvaskandan H, et al. New insights into the pathogenesis and treatment strategies in IgA nephropathy. Glomerular Dis. 2021;2(1):15\u201329.","journal-title":"Glomerular Dis"},{"issue":"19","key":"4927_CR19","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","volume":"10","author":"B Knoppova","year":"2021","unstructured":"Knoppova B, Reily C, King RG, et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J Clin Med. 2021;10(19):4501.","journal-title":"J Clin Med"},{"issue":"8","key":"4927_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/jcm7080225","volume":"7","author":"M Wu","year":"2018","unstructured":"Wu M, Chen C, Yiang G, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med. 2018;7(8):225.","journal-title":"J Clin Med"},{"issue":"5","key":"4927_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","volume":"33","author":"SC Yeo","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33(5):763\u201377.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"4927_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82(7):790\u20136.","journal-title":"Kidney Int"},{"issue":"11","key":"4927_CR23","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.3390\/jcm9113549","volume":"9","author":"JS Kim","year":"2020","unstructured":"Kim JS, Hwang HS, Lee SH, et al. Clinical relevance of serum galactose deficient IgA1 in patients with IgA nephropathy. J Clin Med. 2020;9(11):3549.","journal-title":"J Clin Med"},{"issue":"1","key":"4927_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/mi.2007.6","volume":"1","author":"AJ Macpherson","year":"2008","unstructured":"Macpherson AJ, McCoy KD, Johansen F, et al. The immune geography of IgA induction and function. Mucosal Immunol. 2008;1(1):11\u201322.","journal-title":"Mucosal Immunol"},{"issue":"11","key":"4927_CR25","doi-asserted-by":"publisher","first-page":"e3099","DOI":"10.1097\/MD.0000000000003099","volume":"95","author":"Y Zhai","year":"2016","unstructured":"Zhai Y, Zhu L, Shi S, et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Med (Baltim). 2016;95(11):e3099.","journal-title":"Med (Baltim)"},{"issue":"Suppl 2","key":"4927_CR26","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","volume":"16","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii9\u201318.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4927_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20\u201331.","journal-title":"N Engl J Med"},{"key":"4927_CR28","unstructured":"Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial. N Engl J Med, 2025:10\u20131056."},{"key":"4927_CR29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4927_CR30","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"3","key":"4927_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker A. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4927_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68(3):392\u2013401.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4927_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","volume":"96","author":"JR Myette","year":"2019","unstructured":"Myette JR, Kano T, Suzuki H, et al. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96(1):104\u201316.","journal-title":"Kidney Int"},{"issue":"2","key":"4927_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391\u2013402.","journal-title":"Kidney Int"},{"issue":"10417","key":"4927_CR35","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"6","key":"4927_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392(6):544\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"4927_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392(6):531\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"4927_CR38","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","volume":"60","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60(3):1131\u201340.","journal-title":"Kidney Int"},{"issue":"1","key":"4927_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.ajkd.2014.02.020","volume":"64","author":"LA Inker","year":"2014","unstructured":"Inker LA, Levey AS, Pandya K, et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014;64(1):74\u201385.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4927_CR40","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1681\/ASN.2012111118","volume":"24","author":"TC Turin","year":"2013","unstructured":"Turin TC, James M, Ravani P, et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol. 2013;24(10):1661\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"4927_CR41","doi-asserted-by":"publisher","first-page":"f324","DOI":"10.1136\/bmj.f324","volume":"346","author":"D Nitsch","year":"2013","unstructured":"Nitsch D, Grams M, Sang Y, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.","journal-title":"BMJ"},{"issue":"7","key":"4927_CR42","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"4927_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"ECG The","year":"2023","unstructured":"The ECG, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"4927_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"4927_CR45","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"4927_CR46","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024;15:1436923.","journal-title":"Front Immunol"},{"issue":"10","key":"4927_CR47","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","volume":"28","author":"AM Sevillano","year":"2017","unstructured":"Sevillano AM, Guti\u00e9rrez E, Yuste C, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089\u201399.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4927_CR48","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1681\/ASN.2017060639","volume":"28","author":"R Coppo","year":"2017","unstructured":"Coppo R, Fervenza FC. Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker. J Am Soc Nephrol. 2017;28(10):2831\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"4927_CR49","doi-asserted-by":"publisher","first-page":"1209394","DOI":"10.3389\/fimmu.2023.1209394","volume":"14","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Wang W, Li Y, et al. Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis. Front Immunol. 2023;14:1209394.","journal-title":"Front Immunol"},{"issue":"11","key":"4927_CR50","doi-asserted-by":"publisher","first-page":"e206865","DOI":"10.1371\/journal.pone.0206865","volume":"13","author":"Y Wada","year":"2018","unstructured":"Wada Y, Matsumoto K, Suzuki T, et al. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS ONE. 2018;13(11):e206865.","journal-title":"PLoS ONE"},{"issue":"11","key":"4927_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1681\/ASN.20223311S1783d","volume":"33","author":"K Molyneux","year":"2022","unstructured":"Molyneux K, Nawaz N, Taylor S, et al. Treatment with Nefecon reduces circulating levels of galactose-deficient IgA1 in patients with IgA nephropathy in the NefIgArd clinical trial. J Am Soc Nephrol. 2022;33(11):783\u20134.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4927_CR52","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","volume":"97","author":"Y Makita","year":"2020","unstructured":"Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340\u20139.","journal-title":"Kidney Int"},{"issue":"4","key":"4927_CR53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/path.6353","volume":"264","author":"M Horie","year":"2024","unstructured":"Horie M, Akiyama Y, Katoh H, et al. APRIL\/BAFF upregulation is associated with clonal B-cell expansion in Hunner-type interstitial cystitis. J Pathol. 2024;264(4):383\u201395.","journal-title":"J Pathol"},{"issue":"29","key":"4927_CR54","doi-asserted-by":"publisher","first-page":"e1890658175","DOI":"10.1073\/pnas.2404309121","volume":"121","author":"M Eslami","year":"2024","unstructured":"Eslami M, Schuepbach-Mallepell S, Diana D, et al. Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues. Proc Natl Acad Sci U S A. 2024;121(29):e1890658175.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4927_CR55","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","volume":"106","author":"CK Cheung","year":"2024","unstructured":"Cheung CK, Barratt J, Lafayette R, et al. Targeting APRIL in the treatment of glomerular diseases. Kidney Int. 2024;106(5):806\u201318.","journal-title":"Kidney Int"},{"issue":"3","key":"4927_CR56","first-page":"143","volume":"4","author":"SE Sloan","year":"2018","unstructured":"Sloan SE, Myette JR, Shriver Z, et al. Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal targeting april, for the treatment of igan in a GLP toxicology study in cynomolgus monkeys. Kidney Dis. 2018;4(3):143.","journal-title":"Kidney Dis"},{"issue":"5","key":"4927_CR57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","volume":"7","author":"M Mathur","year":"2022","unstructured":"Mathur M, Barratt J, Suzuki Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG(2) monoclonal antibody, in healthy volunteers. Kidney Int Rep. 2022;7(5):993\u20131003.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"4927_CR58","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186\u2013205.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04927-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:03:50Z","timestamp":1778191430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4927"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04927-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}